TC BioPharm (Holdings) plc

TC Biopharm (Holdings) PLC is a GB-based company operating in Biotechnology industry. The company employs 41 full-time employees The company went IPO on 2022-02-23. TC BioPharm (Holdings) plc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies (GD-Ts) for the treatment of cancer with human efficacy data in acute myeloid leukemia. The firm is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - phase IIb/III pivotal trial in treatment of acute myeloid leukemia using its proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide. Its lead product is TCB-008. In addition to unmodified allogenic GD-Ts for treatment of blood cancers, the Company is also developing an expanded platform for TCB-008 use case in anti-fungal, anti-viral and anti-microbial diseases. Its unmodified cell therapy, used in the treatment of acute myeloid leukemia, is supplied under the name OmnImmune. The company is also developing a range of genetically modified CAR-T products for the treatment of solid cancers.